Abstract: The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.

Abstract: Methods for identifying a hyaluronidase 2 (HYAL2) specific inhibitor, which selectively inhibits HYAL2 activity, but does not substantially affect the activity of non-inflammatory hyaluronidases, are provided. Also provided are HYAL2 specific inhibitors obtained using such a method. In addition, methods for ameliorating an inflammatory disorder or vasculitis condition by specifically inhibiting HYAL2 is provided.